– USA – New York – Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced the appointment of Daniel P. Regan to the Company’s Board of Directors.
Daniel P. Regan, 49, joins the Keryx Board of Directors with broad pharmaceutical leadership experience across the spectrum of global commercialization, sales and marketing of novel therapies for the treatment of patients with chronic kidney disease. From 1999 to 2011, Mr. Regan held positions of increasing responsibility at Genzyme/Sanofi (NYSE:SNY) leading multi-functional teams in sales, marketing and commercialization of the renal products. Mr. Regan’s career at Genzyme included his appointment as Global General Manager, Senior Vice President of the Renal franchise, where he was directly responsible for all aspects of worldwide renal commercial operations, including the Renagel®/Renvela® phosphate binder franchise and the worldwide launch of Renvela®, growing the renal franchise to global revenue approaching $1 billion. Mr. Regan is currently Chief Commercial Officer of Intercept Pharmaceuticals (Nasdaq:ICPT). From 2011 to 2012, Mr. Regan served as Chief Commercial Officer of Inspiration Biopharmaceuticals, which sold its main asset to Baxter International. Mr. Regan has a B.A. degree in Economics from the University of Massachusetts.
“We are extremely excited to have Dan Regan join our board of directors,” said Ron Bentsur, the Company’s Chief Executive Officer. “Dan brings forth tremendous commercialization experience and a wealth of knowledge in the renal space. We look forward to leveraging his expertise towards the potential launch of ZerenexTM (ferric citrate coordination complex), our drug candidate for the treatment of hyperphosphatemia in dialysis patients.”
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate coordination complex), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Keryx has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease on dialysis, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA), and the Company has submitted a New Drug Application to the FDA. The Marketing Authorization Application filing with the European Medicines Agency (EMA) is pending submission. Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stages 3 to 5 non-dialysis dependent chronic kidney disease. In addition, Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease. Keryx is headquartered in New York City.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.